Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin Diseases, Eczematous

ClinicalTrials.gov lists 1,867 trials for Skin Diseases, Eczematous or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 58.

MeSH D017443 Skin and Connective Tissue Diseases C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 219 Phase 1/2 Phase 1/2 52 Phase 2 Phase 2 376 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 254 Phase 4 Phase 4 163 Not applicable Not applicable 441 Observational Observational 340 Phase 1 Phase 1 219 Phase 1/2 Phase 1/2 52 Phase 2 Phase 2 376 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 254 Phase 4 Phase 4 163 Not applicable Not applicable 441 Observational Observational 340

Trials per phase (log scale)

1 more section with rows

20 of the 1,867 trials are tagged with Skin Diseases, Eczematous itself; the rest are tagged with a narrower condition beneath it.

Get the Skin Diseases, Eczematous report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin Diseases, Eczematous trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 149

1994: 1 trials (Observational 1) 1996: 2 trials (Observational 1, Not applicable 1) 1997: 1 trials (Observational 1) 1998: 2 trials (Observational 1, Phase 3 1) 1999: 2 trials (Not applicable 1, Phase 2/3 1) 2000: 3 trials (Not applicable 1, Phase 2 1, Phase 1/2 1) 2001: 6 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 1) 2002: 7 trials (Observational 1, Not applicable 1, Phase 4 3, Phase 3 2) 2003: 10 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 4, Phase 1 1) 2004: 33 trials (Observational 3, Not applicable 4, Phase 4 13, Phase 3 10, Phase 2 1, Phase 1 2) 2005: 33 trials (Observational 9, Not applicable 5, Phase 4 9, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 2) 2006: 24 trials (Observational 6, Not applicable 1, Phase 4 4, Phase 3 1, Phase 2 10, Phase 1 2) 2007: 31 trials (Observational 6, Not applicable 2, Phase 4 11, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2008: 46 trials (Observational 7, Not applicable 7, Phase 4 9, Phase 3 7, Phase 2 7, Phase 1/2 3, Phase 1 6) 2009: 56 trials (Observational 9, Not applicable 13, Phase 4 10, Phase 3 2, Phase 2 16, Phase 1/2 1, Phase 1 5) 2010: 45 trials (Observational 5, Not applicable 14, Phase 4 8, Phase 3 3, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 4) 2011: 51 trials (Observational 8, Not applicable 16, Phase 4 1, Phase 3 6, Phase 2 11, Phase 1/2 2, Phase 1 7) 2012: 46 trials (Observational 7, Not applicable 11, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 4) 2013: 57 trials (Observational 9, Not applicable 14, Phase 4 2, Phase 3 7, Phase 2 22, Phase 1/2 1, Phase 1 2) 2014: 57 trials (Observational 9, Not applicable 16, Phase 4 4, Phase 3 9, Phase 2 10, Phase 1/2 2, Phase 1 7) 2015: 70 trials (Observational 12, Not applicable 14, Phase 4 5, Phase 3 5, Phase 2/3 1, Phase 2 19, Phase 1/2 2, Phase 1 12) 2016: 63 trials (Observational 10, Not applicable 18, Phase 4 3, Phase 3 5, Phase 2 17, Phase 1/2 3, Phase 1 7) 2017: 73 trials (Observational 13, Not applicable 19, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 17, Phase 1/2 3, Phase 1 10) 2018: 120 trials (Observational 17, Not applicable 26, Phase 4 9, Phase 3 29, Phase 2 27, Phase 1 12) 2019: 121 trials (Observational 27, Not applicable 23, Phase 4 8, Phase 3 14, Phase 2 29, Phase 1/2 2, Phase 1 18) 2020: 104 trials (Observational 24, Not applicable 19, Phase 4 7, Phase 3 15, Phase 2/3 2, Phase 2 22, Phase 1/2 7, Phase 1 8) 2021: 124 trials (Observational 34, Not applicable 30, Phase 4 4, Phase 3 11, Phase 2/3 1, Phase 2 24, Phase 1/2 5, Phase 1 15) 2022: 135 trials (Observational 24, Not applicable 38, Phase 4 8, Phase 3 21, Phase 2/3 3, Phase 2 20, Phase 1/2 5, Phase 1 16) 2023: 149 trials (Observational 30, Not applicable 38, Phase 4 15, Phase 3 19, Phase 2/3 3, Phase 2 25, Phase 1/2 4, Phase 1 15) 2024: 129 trials (Observational 22, Not applicable 37, Phase 4 3, Phase 3 30, Phase 2 18, Phase 1/2 2, Phase 1 17) 2025: 136 trials (Observational 26, Not applicable 36, Phase 4 4, Phase 3 13, Phase 2/3 2, Phase 2 30, Phase 1/2 1, Phase 1 24)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 116
2025 136
2024 129
2023 149
2022 135
2021 124
2020 104
2019 121
2018 120
2017 73

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 140 trials starting in 2026 and about 130 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 152 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 1,271 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin Diseases, Eczematous trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 219
Phase 1/2 52
Phase 2 376
Phase 2/3 19
Phase 3 254
Phase 4 163
Not applicable 441
Observational 340
Expanded access 3

How many Skin Diseases, Eczematous trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 76
Recruiting 176
Enrolling by invitation 17
Active, not recruiting 77
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin Diseases, Eczematous trials? (14)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 58
Sanofi 40
LEO Pharma 38
National Institute of Allergy and Infectious Diseases (NIAID) 38
AbbVie 31

Showing 5 of 14 sponsors.

Start your 14-day trial Email me all 14 sponsors as a PDF

Which drugs are being tested for Skin Diseases, Eczematous? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Abrocitinib 29
Pimecrolimus 21
Tralokinumab 18
Nemolizumab 14
Rocatinlimab 12

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dupilumab/Dupixent 79
Vehicle Cream 24
Lebrikizumab Pen 24
upadacitinib 15mg/day 22
IR Tacrolimus 17

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin Diseases, Eczematous trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Dermatitis atopic 201 60
Asthma 145 41
Pneumonia 126 46
Wheezing 90 6
Gastroenteritis 71 9

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Skin Diseases, Eczematous? (3)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The Endocannabinoid System and Its Role in Eczematous Dermatoses. Dermatitis : contact, atopic, occupational, drug 2017 Yes
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010 Yes
Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2003 No

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages